U.S. Food and Drug Administration Approves Two Opdivo® (nivolumab)-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma

On May 27, 2022

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219

Related Post

Duke Energy assessing damage and beginning restoration after strong storm cuts power for about 100,000 customers across the Cincinnati region and Northern Kentucky

Federal Realty Investment Trust Announces Second Quarter 2022 Earnings Release Date and Conference Call Information

Mattel Announces Second Quarter 2022 Financial Results Conference Call